COVID-19 infection increases diabetes risk, study confirms
In a study from Cedars-Sinai, scientists have confirmed that people who have had COVID-19 have an increased risk for new-onset diabetes—the biggest contributor to...
Widely used mental disease drug may reduce COVID-19 symptoms
A recent study from the University of Barcelona found that psychiatric medications can give some protection against COVID-19, with the common antidepressant fluvoxamine showing...
Your 1st COVID-19 vaccination could ‘hurt’ subsequent boosters
In a study from Northwestern Medicine, scientists found the first COVID-19 vaccination could 'hurt' subsequent boosters.
They found the antibodies generated by those prior vaccinations...
Lingering symptoms common after COVID hospitalization
In a study from the University of Michigan, scientists found about half of adults treated at hospitals for COVID-19 have experienced lingering symptoms, financial...
Organ damage in long COVID can be long-lasting
In a study from the UCL Institute of Health Informatics, scientists examined organ impairment in long COVID patients over 12 months.
Why men are at higher risk of COVID-19
Scientists found sex-specific differences in a type of immune cell called regulatory T cells, or "Treg cells," and in the production of proteins called antibodies, as part of the response to COVID-19 infection.
Scientists find a possible cause of long COVID
In two studies from the University of Colorado, scientists found a possible cause of long COVID.
A constant puzzle to solve since the first year...
Certain pollutants may increase risk of COVID-19, study finds
Scientists found that high levels of certain chemical pollutants in the blood are linked to an increased risk of COVID-19 disease.
Research shows very strong brain abnormalities post-COVID
About one in five adults will develop long-term effects from COVID-19, according to the U.S. Centers for Disease Control and Prevention.
A recent study from the Indian...
Paxlovid effectively reduces risks of hospitalization and death in Omicron infection
In a study from Public Health Ontario and elsewhere, scientists found nirmatrelvir–ritonavir (Paxlovid) strongly reduced the likelihood of hospitalization or death from COVID-19 in...